{"id":"hydroxychloroquine-reduced","safety":{"commonSideEffects":[{"rate":null,"effect":"Retinopathy"},{"rate":"5-10","effect":"Nausea and gastrointestinal upset"},{"rate":"3-5","effect":"Headache"},{"rate":"2-3","effect":"Dizziness"},{"rate":"1-3","effect":"Pruritus"},{"rate":null,"effect":"Myopathy"}]},"_chembl":{"chemblId":"CHEMBL1535","moleculeType":"Small molecule","molecularWeight":"335.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydroxychloroquine accumulates in lysosomes and impairs autophagy and antigen presentation, thereby suppressing T-cell and B-cell activation. It also inhibits toll-like receptor signaling and reduces production of pro-inflammatory cytokines such as TNF-α and IL-6, making it effective in autoimmune and inflammatory conditions.","oneSentence":"Hydroxychloroquine is a quinoline antimalarial and immunomodulatory agent that inhibits lysosomal function and reduces inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:22.538Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Systemic lupus erythematosus"},{"name":"Malaria prophylaxis and treatment"},{"name":"Discoid lupus erythematosus"}]},"trialDetails":[{"nctId":"NCT02615938","phase":"PHASE2","title":"Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)","status":"TERMINATED","sponsor":"Matthias Griese","startDate":"2015-08-21","conditions":"Interstitial Lung Disease, Diffuse Parenchymal Lung Disease, Children´s Interstitial Lung Disease","enrollment":35},{"nctId":"NCT06652113","phase":"NA","title":"Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-11-15","conditions":"Recurrent Pregnancy Loss, Euthyroid With Thyroid Antibodies","enrollment":796},{"nctId":"NCT03037437","phase":"PHASE2","title":"Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-02-16","conditions":"Hepatocellular Cancer","enrollment":64},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT04310462","phase":"NA","title":"Effectiveness of an EHR Interface to Reduce Dosage of Hydroxychloroquine","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2017-02-01","conditions":"Rheumatic Diseases","enrollment":65},{"nctId":"NCT06512766","phase":"","title":"a Retrospective Study on the Systemic Treatment of LPP and FFA","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-09-23","conditions":"Cicatricial Alopecia, Lichen Planopilaris, Lichen Plano-Pilaris","enrollment":315},{"nctId":"NCT04316494","phase":"PHASE4","title":"Hydroxychloroquine in ANCA Vasculitis Evaluation","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2020-12-17","conditions":"ANCA Associated Vasculitis, Microscopic Polyangiitis, Churg-Strauss Syndrome","enrollment":43},{"nctId":"NCT05689359","phase":"PHASE2","title":"Evaluation of Hydroxychloroquine to Prevent CIPN","status":"WITHDRAWN","sponsor":"University of Arizona","startDate":"2024-06","conditions":"Breast Cancer, Gynecologic Cancer, Early-stage Breast Cancer","enrollment":""},{"nctId":"NCT00579878","phase":"PHASE3","title":"Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-03-27","conditions":"Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT05980156","phase":"PHASE4","title":"Comparing Chemoprevention Drugs for School-based Malaria Control","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2023-02-13","conditions":"Malaria,Falciparum, Anemia in Children","enrollment":646},{"nctId":"NCT01491815","phase":"PHASE4","title":"Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2012-12-14","conditions":"Rheumatoid Arthritis","enrollment":812},{"nctId":"NCT02466581","phase":"PHASE4","title":"Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2015-02-03","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT05013463","phase":"PHASE2","title":"Hydroxychloroquine and Indapamide in SPMS","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2021-10-01","conditions":"Multiple Sclerosis, Secondary Progressive","enrollment":35},{"nctId":"NCT03122431","phase":"PHASE4","title":"Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-06-05","conditions":"Systemic Lupus Erythematosus (SLE), Juvenile SLE, Cutaneous Lupus","enrollment":93},{"nctId":"NCT02913157","phase":"PHASE2","title":"Hydroxychloroquine in Primary Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2016-11","conditions":"Multiple Sclerosis, Primary Progressive","enrollment":35},{"nctId":"NCT04403100","phase":"PHASE3","title":"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: \"The Hope Coalition - 1\"","status":"UNKNOWN","sponsor":"Cardresearch","startDate":"2020-06-03","conditions":"COVID-19, Coronavirus Infection, Virus Disease","enrollment":1968},{"nctId":"NCT04386447","phase":"PHASE2","title":"Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19","status":"WITHDRAWN","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2020-09-01","conditions":"Covid-19, Corona Virus Infection, SARS-CoV 2","enrollment":""},{"nctId":"NCT03856866","phase":"PHASE2","title":"Hydroxychloroquine Administration for Reduction of Pexophagy","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2019-01-11","conditions":"Zellweger Syndrome, Peroxisome Biogenesis Disorders","enrollment":3},{"nctId":"NCT04569890","phase":"NA","title":"Treatment of Pregnancy RA","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-12-01","conditions":"Rheumatoid Arthritis, Pregnancy Related","enrollment":100},{"nctId":"NCT04491994","phase":"PHASE3","title":"Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression","status":"COMPLETED","sponsor":"UNICEF","startDate":"2020-04-10","conditions":"Covid19, Progression","enrollment":540},{"nctId":"NCT04395170","phase":"PHASE2, PHASE3","title":"Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.","status":"UNKNOWN","sponsor":"Lifefactors Zona Franca, SAS","startDate":"2020-09","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":75},{"nctId":"NCT04354441","phase":"PHASE2","title":"Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women","status":"WITHDRAWN","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2020-05","conditions":"COVID-19, SARS-CoV-2, Pregnant Women","enrollment":""},{"nctId":"NCT04153201","phase":"NA","title":"Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2013-01-15","conditions":"Antiphospholipid Syndrome","enrollment":50},{"nctId":"NCT01978184","phase":"PHASE2","title":"Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine","status":"COMPLETED","sponsor":"Nathan Bahary, MD","startDate":"2013-11","conditions":"Pancreatic Cancer","enrollment":104},{"nctId":"NCT03400865","phase":"NA","title":"Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas","status":"UNKNOWN","sponsor":"Zhebao Wu","startDate":"2018-10-25","conditions":"Resistance, Disease, Prolactinoma","enrollment":30},{"nctId":"NCT02942381","phase":"PHASE2","title":"A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2016-09-13","conditions":"IgA Patients, Hydroxychloroquine","enrollment":60},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT01326533","phase":"PHASE4","title":"Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2011-03","conditions":"Pre-diabetes","enrollment":32},{"nctId":"NCT02351752","phase":"PHASE4","title":"Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study","status":"COMPLETED","sponsor":"LLiu","startDate":"2015-01","conditions":"Primary IgA Nephropathy","enrollment":20},{"nctId":"NCT02200146","phase":"PHASE3","title":"Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).","status":"COMPLETED","sponsor":"University of Milano Bicocca","startDate":"2009-03","conditions":"Pulmonary Sarcoidosis","enrollment":94},{"nctId":"NCT00065806","phase":"PHASE3","title":"Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)","status":"COMPLETED","sponsor":"Laura Schanberg","startDate":"2003-09","conditions":"Lupus Erythematosus, Systemic","enrollment":221},{"nctId":"NCT00413361","phase":"PHASE4","title":"The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-06","conditions":"Systemic Lupus Erythematosus","enrollment":543},{"nctId":"NCT00422227","phase":"PHASE4","title":"Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-06","conditions":"Rheumatoid Arthritis","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":878,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HCQ reduced"],"phase":"marketed","status":"active","brandName":"Hydroxychloroquine reduced","genericName":"Hydroxychloroquine reduced","companyName":"University of Sao Paulo General Hospital","companyId":"university-of-sao-paulo-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxychloroquine is a quinoline antimalarial and immunomodulatory agent that inhibits lysosomal function and reduces inflammatory cytokine production. Used for Rheumatoid arthritis, Systemic lupus erythematosus, Malaria prophylaxis and treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}